The Motley Fool

Why I’d buy these 2 UK shares today for long-term growth

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Graph Falling Down in Front Of United Kingdom Flag
Image source: Getty Images

With many expecting the UK economy to bounce back this year after the damning impacts of the pandemic, I think now is a great time for seeking UK shares to buy and hold for the long term. My colleague Jonathan Smith recently looked at cheap UK shares, highlighting the benefits of owning these for a decade. With that said, here I’ll look at two UK shares that I’d buy today for long-term growth.

Scottish Mortgage Investment Trust

The Scottish Mortgage Investment Trust (LSE: SMIT) has seen spectacular returns over the past 18 months. Up over 135% from the beginning of 2020, and 13% year-to-date, the trust run by Baillie Gifford continues to go from strength to strength. I like it because it measures performance over a five-year period. Within the last five years, SMIT has seen returns of over 345%. Its top holdings are diversified — and as of June 2021 included Illumina, Moderna, and NIO. To further this, I have confidence in the fund managers and their judgment; seen by their recent decision to halve SMIT’s position in Tesla.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

The trust saw a near 30% fall in February, in part due to the tech sell-off, which highlights that it’s not immune to periods of volatility, regardless of its diverse portfolio. However, for me, this doesn’t pose an issue. I’d buy this UK share today to own it for a minimum of five years. If the next five years follow a similar pattern to the previous five, there’s the potential for me to see a healthy return. Large exposure to tech stocks, however, could lead to issues in the future as we see the uncertainty surrounding regulation


Recently in the spotlight due to its Covid-19 vaccine, AstraZeneca (LSE: AZN) is up 12% in the past six months. Although this UK share has been volatile over the past year amid concerns over possible vaccine side-effects and late deliveries, late July saw the release of its half-year results for 2021. There were many positives to take away. Revenues were up 23% (14% without vaccine sales) compared to half-year 2020, while product sales rose by 24%. With this said, an issue was the 25% fall in profits for Q2 2021.

However, what really draws me to AstraZeneca is its long-term outlook. As highlighted in its latest results, its recent acquisition of Alexion Pharmaceuticals should help the company achieve a transition to sustainable growth, allowing it to expand into the rare disease medicines industry through Alexion’s complement-biology platform. Pascal Soriot, the firm’s CEO, also mentioned the continued investment in R&D, showing a strong focus on a long-term outlook.

Why I’m buying

These are two UK shares that I deem a good addition to my portfolio. Both stocks have seen solid growth over the past five years – and I expect this to continue. While SMIT offers access to a variety of sectors, most notably the expanding tech sector, AstraZeneca is in a pharmaceutical industry that has the capability to flourish and grow in the future. With the UK economy still on the road to recovery post-pandemic, I think now is the perfect time for me to buy.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Charlie Keough owns shares of Scottish Mortgage Investment Trust and NIO. The Motley Fool UK owns shares of and has recommended NIO Inc. and Tesla. The Motley Fool UK has recommended Illumina and Moderna Inc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.